This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo
by Zacks Equity Research
Seattle Genetics (SGEN) to win a milestone fee from GlaxoSmithKline following the EU approval of Blenrep, developed by the latter. Blenrep is made using the company's proprietary technology.
Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales
by Zacks Equity Research
Seattle Genetics (SGEN) reports a narrower-than-expected loss and beats sales estimates in the second quarter of 2020.
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 6.90% and 8.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck's Keytruda Gets Priority Review for Lymphoma Indication
by Zacks Equity Research
FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.
Seattle Genetics' Adcetris Progresses Well Amid Competition
by Zacks Equity Research
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. Further, label expansions of the drug should continue to boost the top line.
Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF
by Sweta Killa
In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.
Why Is Seattle Genetics (SGEN) Up 14.6% Since Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck's (MRK) Keytruda Successful in Several Cancer Studies
by Zacks Equity Research
Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.
Seattle Genetics' Adcetris Label Expands in EU for Lymphoma
by Zacks Equity Research
Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.
Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners
by Sweta Killa
Invesco QQQ (QQQ), which tracks the Nasdaq 100 Index, joined the $100 billion club of AUM last week.
Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.
Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q1 Loss
by Zacks Equity Research
Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.
BioDelivery (BDSI) Beats on Q1 Earnings, Withdraws Guidance
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues. Stock up.
Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q1 revenues increase year over year.
Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the first quarter of 2020.
Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales
by Zacks Equity Research
Seattle Genetics (SGEN) reports narrower-than-expected loss in Q1 while its revenues too beat estimates.
Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat
by Zacks Equity Research
Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.
Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 20.99% and 10.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.
Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates for the first quarter of 2020. The company withdraws its previously provided outlook for 2020 amid uncertainty related to coronavirus.
Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Seattle Genetics (SGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.
What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?
by Zacks Equity Research
During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.